By 2025, the FDA had approved six CAR-T cell products, primarily targeting CD19+ B-cell malignancies (such as diffuse large B-cell lymphoma and acute lymphoblastic leukemia) and BCMA+ multiple myeloma (20). Here, TNFRSF17 is linked to plasma cell myeloma.